Use of the CD2 signaling domain in second-generation chimeric antigen receptors
US11597754B2 · kind B2 · utility
2Cited by
30References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 2, 2019 |
| Grant date | Mar 7, 2023 |
| Priority date | — |
| Expiry date | Jul 19, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell expressing a CAR having an antigen binding domain, a transmembrane domain, a CD2 signaling domain, and a CD3 zeta signaling domain. The invention also includes incorporating CD2 into the CAR to alter the cytokine production of CAR-T cells in both negative and positive directions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.